替诺福韦酯治疗ALT轻度升高的初治慢性乙型肝炎台湾患者:TORCH-B随机对照试验
TORCH-B是在台湾6家教学医院开展的多中心、双盲、安慰剂对照、平行组随机试验,纳入160例25-70岁、HBV DNA>2000 IU/mL且ALT为1-2倍正常上限的初治慢性乙型肝炎患者,按1:1随机接受替诺福韦酯300 mg每日一次或安慰剂治疗3年。
要点
- 替诺福韦酯可降低ALT轻度升高的初治慢性乙型肝炎患者肝纤维化进展风险。
- 对坏死性炎症进展的影响未达统计学显著性。
- 替诺福韦酯组需加用恩替卡韦补救的急性肝炎发作更少。
核心结论
- 替诺福韦酯可降低ALT轻度升高的非肝硬化慢性乙型肝炎患者肝纤维化进展风险。
- 替诺福韦酯对坏死性炎症进展的影响无统计学显著性。
研究设计与样本
- TORCH-B为多中心、双盲、安慰剂对照、平行组随机试验,在台湾6家教学医院开展。
- 纳入25-70岁、HBV DNA>2000 IU/mL且ALT为1-2倍正常上限的初治慢性乙型肝炎患者,排除肝硬化和既往抗病毒治疗者。
- 160例按1:1随机接受替诺福韦酯300 mg每日一次(n=79)或安慰剂(n=81)治疗3年,按中心分层、固定区组大小10。
- 共同主要结局为Knodell量表坏死性炎症严重度变化和Ishak量表纤维化分期变化,在146例有配对肝活检的改良意向性分析人群中评估。
主要发现
- 两组不良事件发生情况相似,无患者死亡。
临床怎么用
- 对于HBV DNA>2000 IU/mL且ALT为1-2倍正常上限的非肝硬化初治慢性乙型肝炎患者,可考虑使用替诺福韦酯以降低肝纤维化进展风险。
- 治疗期间需监测急性肝炎发作,必要时加用恩替卡韦补救。
局限性
- 共同主要结局仅在146例有配对肝活检的患者中评估,非全部随机化人群。
- 坏死性炎症进展的组间差异未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiviral therapy for patients with non-cirrhotic chronic hepatitis B and minimally raised alanine aminotransferase (ALT) is controversial. We aimed to investigate the efficacy and safety of tenofovir disoproxil fumarate in reducing the risk of disease progression in this patient population. METHODS: TORCH-B is a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial done at six teaching hospitals in Taiwan that enrolled patients with chronic hepatitis B. Eligible patients were aged 25-70 years and had substantial viraemia (viral DNA >2000 IU/mL) and minimally raised serum ALT concentrations more than one-fold but less than two-fold the upper limit of normal (ULN). Exclusion criteria included liver cirrhosis and previous antiviral treatment. Eligible participants were randomly assigned (1:1), stratified by site with a fixed block size of ten, to receive either 300 mg of oral tenofovir disoproxil fumarate or placebo once daily for 3 years. The participants, investigators, research coordinators, pathologists, laboratory personnel, and staff involved in patient care or assessment were masked to treatment assignment. 0·5 mg/day of oral entecavir was added to rescue acute hepatitis flare. The coprimary outcomes were change in necroinflammation severity on the Knodell scale and change in fibrosis stage on the Ishak scale and were evaluated in the modified intention-to-treat population, which comprised all patients with paired liver biopsies. Safety was evaluated in all patients who were randomly assigned. This trial is registered at ClinicalTrials.gov, NCT01522625, and is completed. FINDINGS: From Jan 30, 2012, to Nov 10, 2015, 875 patients were screened and 160 were randomly assigned to receive either tenofovir disoproxil fumarate (n=79) or placebo (n=81). The coprimary outcomes were assessed in 146 patients (73 in each group). Liver fibrosis progressed (an increase of ≥1 stage) in 19 (26%, 95% CI 17-38) of 73 patients in the tenofovir disoproxil fumarate group and in 34 (47%, 35-59) of 73 patients in the placebo group (relative risk [RR] 0·56, 95% CI 0·35-0·88; p=0·013), whereas necroinflammation progressed (an increase of ≥2 points) in five (7%, 95% CI 2-15) patients in the tenofovir disoproxil fumarate group and in 12 (16%, 9-27) patients in the placebo group (RR 0·42, 95% CI 0·15-1·12; p=0·084). Two (3%) of 79 patients in the tenofovir disoproxil fumarate group and 13 (16%) of 81 patients in the placebo group had acute hepatitis flare requiring add-on entecavir (RR 0·16, 95% CI 0·04-0·68; p=0·013). The two groups were otherwise similar in occurrences of adverse events. No patients died. INTERPRETATION: Tenofovir disoproxil fumarate reduces the risk of progression in liver fibrosis in patients with chronic hepatitis B and minimally raised ALT, but its effect on necroinflammation is non-significant. FUNDING: The Taiwan Ministry of Science and Technology, E-Da Hospital, the Taipei Institute of Pathology, Gilead Sciences.
引用
- Hsu YC, Chen CY, Chang IW, et al. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial. Lancet Infect Dis. 2021. PMID: 33524314. doi:10.1016/S1473-3099(20)30692-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。